RS-2023-00217346

Completion of non-clinical studies and IND authorization for a 3rd generation multiple sclerosis drug candidate based on biased modulation that overcomes the limitations of cardiac side effects

Cureverse Co., Ltd.

CUREVERSE
큐어버스

IMMUNOLOGY | **Preclinical**

Product Type	Small molecule
Indication	multiple sclerosis
Target	S1P1
MoA(Mechanism of Action)	Peripheral lymphocyte reduce → Inhibition of Autoimmune & Neuro-inflammation (S1P1 agonist → Functional antagonist)
Competitiveness	CV-02 is a next-generation S1P1 modulator that minimizes cardiac side effects due to G-protein-mediated signals through signal biased control technology for S1P1 receptor 
Development Stage	Preclinical
Route of Administration	PO

kddf_bd@kddf.org
KDDF Business Development Team

KDDF
Korea Drug Development Fund